Guiding Treatment Decisions in Cancer using Protein Biomarker Measurements: from Design to Utility
Prof. Stephen Pennington, University College Dublin, speaking at Discovery Chemistry Congress 2013.
Robust Three-dimensional Tools to Design Inhibitors Against Drug Targets Which Lack Explicit Specificity
Dr. Moses Mohandas Prabu, The Commonwealth Medical College, speaking at Discovery Chemistry Congress 2013.
Chemical Proteomics: Drug Targets, Drug Selectivity, MoA and Resistance
Dr. Guillaume Médard, Technische Universität München, speaking at Discovery Chemistry Congress 2013.
Detection of Rare Cancer Cell Phenotypes by Single Cell Analysis of Surface Proteins
Rajan Kumar, Genome Data Systems, Inc., speaking at Lab-on-a-Chip World Congress 2012
The Use of -omic Technologies for Biomarker Development
Michael Pfaffl, Principal Investigator, Technical University of Munich, speaking at Genomics Research Asia 2012
Bicyclic Peptides with Antibody-Like Binding Affinity and Specificity
Dr Vanessa Baeriswyl, EPFL, speaking at Stem Cells & Bioprocessing Europe 2012.
Typical Phospho-form Abundance Profile of Cellular ERK Discovered by Quantitative UPLC-MS
Wolf Lehmann, German Cancer Research Center, speaking at Systems Biology Europe 2012
Proteomic and Bioinformatic Approaches to the Development of Biomarker Signatures of Clinical Utility for Prostate Cancer: From Discovery to Targeted Verification
Stephen Pennington, University College Dublin, speaking at Systems Biology Europe 2012
Secretome Proteomics for Tumor Biomarker Discovery
Josep Villanueva, Vall d'Hebron Institute of Oncology (VHIO), speaking at Systems Biology Europe 2012